CRISPR THERAPEUTICS AG (CRSP) Free cash flow 2016–2025
CRISPR THERAPEUTICS AG (CRSP) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$345.9MFY2025 · since FY2016: -$55.9M → -$345.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$345.9M | -139.1% |
| FY2024 | -$144.7M | +46.4% |
| FY2023 | -$269.8M | +49.4% |
| FY2022 | -$532.9M | -216.5% |
| FY2021 | $457.3M | +278.1% |
| FY2020 | -$256.7M | -613.5% |
| FY2019 | $50.0M | +150.5% |
| FY2018 | -$99.0M | -27.1% |
| FY2017 | -$77.9M | -39.4% |
| FY2016 | -$55.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice